Table 4. Hazard ratios for reaching secondary end points according to quintiles of baseline serum cholesterol concentration and the corresponding to a 1-SD increase in serum cholesterol concentration.

			Secondary Endpoint
			Time to Death		Time to Freezing of gait
Cholesterol conc. quintile	Cholesterol conc. (mM)	No. of subjects	HR (95% CI)	Two-tailp-value	HR (95% CI)	Two-tailp-value
1st	≤180.7	153	1.0 (Reference)	–	1.0 (Reference)	–
2nd	180.8–203.9	159	1.09 (0.75–1.59)	0.65	0.73 (0.42–1.28)	0.27
3rd	204.0–222.8	153	1.10 (0.75–1.62)	0.63	1.03 (0.61–1.76)	0.90
4th	222.9–246.7	156	1.16 (0.78–1.72)	0.46	0.83 (0.48–1.44)	0.51
5th	≥246.8	153	1.01 (0.68–1.50)	0.96	0.91 (0.52–1.58)	0.73
1 SDa increase in serum cholesterol concentration			1.01 (0.90–1.15)	0.84	0.97 (0.81–1.16)	0.72
Males
1st	≤178.8	101	1.0 (Reference)	–	1.0 (Reference)	–
2nd	178.9–198.8	103	1.10 (0.71–1.70)	0.67	0.61 (0.30–1.25)	0.18
3rd	198.9–216.6	104	1.16 (0.73–1.83)	0.53	1.18 (0.63–2.20)	0.61
4th	216.7–241.8	103	1.19 (0.76–1.87)	0.45	0.76 (0.39–1.50)	0.43
5th	≥241.8	99	0.89 (0.55–1.45)	0.64	0.88 (0.46–1.70)	0.71
1-SD increase in serum cholesterol concentration			1.00 (0.87–1.15)	0.99	0.93 (0.76–1.15)	0.52
Females
1st	≤185.7	53	1.0 (Reference)	–	1.0 (Reference)	–
2nd	185.8–211.6	54	0.77 (0.30–1.98)	0.59	0.45 (0.15–1.34)	0.15
3rd	211.7–233.6	51	1.19 (0.52–2.72)	0.69	0.39 (0.12–1.25)	0.11
4th	233.7–255.6	53	0.86 (0.36–2.03)	0.73	0.98 (0.36–2.71)	0.97
5th	≥255.7	53	1.26 (0.55–2.90)	0.59	0.57 (0.19–1.71)	0.31
1-SD increase in serum cholesterol concentration			1.12 (0.86–1.47)	0.40	0.97 (0.67–1.39)	0.85

HR = hazard ratio; CI = confidence interval. Models are adjusted for gender (for total cohort), treatment group, baseline age, uric acid concentration, PD subtype, and BMI.

^aA 1-standard deviation (SD) increase indicates an increase of 39.2 mg/dL in all subjects, 37.6 mg/dL in males, and, 41.0 mg/dL in females.